Highest-materiality recent filing
Tempest Therapeutics CFO resigns, appoints new CFO and two independent directors
CFO Nicholas Maestas resigns effective June 5, 2026; Justin Trojanowski named VP Finance, Principal Financial Officer and Corporate Secretary.
Holder exercises 1,172,414 existing warrants at reduced $1.73/share for ~$2M cash gross proceeds.
Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign
Stockholders' equity of $822k vs Nasdaq's $2.5M minimum; 45 days to submit compliance plan by July 6, 2026.
Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003
100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.
Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition
Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.
Tempest Therapeutics raises ~$2M in private placement of stock and warrants
Raised ~$2M gross from private placement of 462,964 shares + pre-funded warrants at $2.16 per unit.
Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026
100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.
Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing
Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.
Tempest raises $4.25M upfront in registered direct offering; warrants add up to $4.1M
1,172,414 shares (or equivalents) sold at $3.625/share in registered direct offering for ~$4.25M gross.
Tempest Therapeutics to acquire four CAR T assets in all-stock deal; CEO change, warrants issued
Acquires ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies for 8,268,495 shares of TPST common stock.
Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process
Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.
Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China
Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.
Issued 405,000 shares at $6.25 each and prefunded warrants for 334,000 shares at $6.249 each.
Tempest Therapeutics transitions CEO, CMO, and CFO to consultants with equity acceleration
CEO Stephen Brady, CMO Samuel Whiting, CFO Nicholas Maestas transitioned to consulting agreements effective June 5, 2025.
Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives
Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.
Tempest Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq notice on April 24, 2025 confirming compliance with Listing Rule 5550(a)(2).
Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review
Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.
Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee
Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.
Tempest Therapeutics announces 1-for-13 reverse stock split effective April 8, 2025
Reverse stock split at 1:13 ratio, effective 5:00 p.m. ET on April 8, 2025.
Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations
Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.
Tempest Therapeutics stockholders approve reverse stock split proposal at ratios up to 1-for-15
Stockholders approved reverse stock split proposal at special meeting on December 3, 2024.
Tempest reports Q3 net loss $10.6M; gets FDA go-ahead for amezalpat Phase 3 in first-line HCC
Net loss of $10.6M ($0.41/sh) in Q3 2024 vs $6.8M ($0.48) in Q3 2023; cash $22.1M, then raised $19.9M net via ATM.
Tempest inks Roche atezolizumab supply deal for Phase 3 liver cancer trial; extends rights plan
Master clinical supply agreement with Roche for free atezolizumab in planned Phase 3 trial of amezalpat (TPST-1120) in first-line unresectable/metastatic HCC.
Tempest reports Q2 2024 financials; amezalpat shows 6-month survival benefit in liver cancer study
Amezalpat median OS 21 months vs 15 months control (6-month improvement); HR 0.65 stable from prior 0.59.
Tempest: amezalpat 6-month OS improvement in HCC (21 vs 15 months); files $205M equity facility
Median OS 21 months for amezalpat arm vs 15 months control, a six-month advantage.
Tempest reports FY2023 net loss $29.5M; positive Phase 1b/2 HCC data for TPST-1120
Net loss $29.5M ($1.91/sh) vs $35.7M in 2022; cash $39.2M, runway into Q2 2025.
Tempest Q3 net loss $6.8M; TPST-1120 shows superiority in liver cancer; cash runway into 2025
Net loss $6.8M ($0.48/share) vs $8.9M ($0.66) in Q3 2022; R&D expense fell to $4.2M from $6.0M.
Tempest TPST-1120 achieves 30% ORR vs 13.3% control in randomized HCC study; adopts poison pill
Confirmed ORR 30% for TPST-1120 arm vs 13.3% control; duration of response not reached.
Tempest Therapeutics receives Nasdaq bid price deficiency notice, 180 days to comply
Nasdaq notified TPST on Sept 6, 2023 that bid price closed below $1.00 for 30 consecutive days.
Tempest Q2 2023 net loss $7.6M; TPST-1120 HCC data shows 74% ORR improvement over control
Cash $17.6M at June 30, 2023, down from $31.2M at Dec 31, 2022.
Tempest Q1 2023 net loss $7.6M ($0.55/shr); positive TPST-1120 HCC data highlighted
Net loss $7.6M ($0.55 per share) vs $8.5M ($1.18) in Q1 2022; cash $22.9M, runway through Q2 2024.
Tempest reports positive early Phase 1b/2 data for TPST-1120 in HCC; ORR improved vs control
Unconfirmed ORR 30% (12/40) for TPST-1120 arm vs 17.2% (5/29) control, a 74.4% relative improvement.
Tempest Therapeutics FY2022 net loss $35.7M; cash $31.2M; TPST-1120 HCC data H1 2023
Cash and equivalents $31.2M as of Dec 31, 2022, down from $51.8M; runway to Q2 2024.
Tempest Therapeutics entered into a First Amendment to Loan and Security Agreement with Oxford Finance LLC on Dec 23, 2022.
the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
the Board of Directors of the Company (the “Board”) appointed Mr. Justin Trojanowski as Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company, in addition to his current role as Corporate Controller, Treasurer and Principal Accounting Officer of the Company.
the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026.
On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the "Company") of her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.
resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board
resignations of Mr. Michael Raab and Ms. Christine Pellizzari from the Board
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.
the Board will appoint Stephen Brady, the Company’s chief executive officer, as president and chief executive officer effective as of the Separation Date
On September 2, 2023, Tom Dubensky, Ph.D. resigned from his role as president and member of the Board of Directors
Max materiality 0.95 · Median 0.65 · Most common event other_material